Max S. Lazar

Articles by Max S. Lazar

  • ICH’s Future Reforms – Its Strengths and Weaknesses

    Wednesday, September 30, 2015
    I recently read with great interest that ICH has embarked on some very significant changes in structure and organization1. While change based upon historical experience can improve effectiveness; some changes sometimes undermine effective ...
  • Current Regulatory Problems Facing API Manufacturers—One Man's Opinion

    Monday, December 01, 2014
    What is going on here? Why are so many problems being encountered by so many Active Pharmaceutical Ingredient (API) manufacturers, especially from India and China? Has the entire industry decided to ignore the rules of the game? Well, here is one man...
  • API Roundtable

    Monday, August 05, 2013
    Active Pharmaceutical Ingredient manufacturers have faced their share of regulatory concerns over the years. In fact, the adoption of the ICH Q7A API GMP Guidance would have never occurred if not for the absence of an accepted API GMP globally. In...
  • One Man’s Opinion

    Wednesday, September 01, 2010
    After 45 years in the drug and API industry, I have seen and experienced many things both as a member of the FDA’s regulated industries and as an active participant and I trust, contributor to the development of policies and practices used to ...
  • API Roundtable

    Saturday, January 01, 2011
    What, in your opinion, is currently the single largest trend with respect to active pharmaceutical ingredients outsourcing and manufacture?
  • Changes That May Be Affecting API

    Sunday, November 01, 2009
    Change is inevitable whether intentional or unplanned. Some people like to write the “C” in CGMP as a small “c” to reflect the fact that “current” really represents a changing set of rules. Such changes can occur in an industry because of shifting ...
  • <<
  • >>